A plaintiff involved in a Lipitor lawsuit has filed a motion seeking to establish a consolidated proceeding for cases alleging type-2 diabetes caused by the medication, according to court records.
According to a motion filed on October 10th with the U.S. Judicial Panel on Multidistrict Litigation (JPML), a total of 62 Lipitor lawsuit claims had been filed in 21 U.S. federal jurisdictions. Based on this number, the Motion urges the Panel to consider a centralization of claims. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502 (JPML))
A separate request to consolidate Lipitor lawsuits was denied earlier this year by the Panel, who said there were not enough claims filed over Lipitor to warrant a federal multidistrict litigation. The new Motion proposes that the proceeding be created in the U.S. District Court, Southern District of California, where 14 lawsuits have already been filed.
Earlier in October, state court-filed Lipitor lawsuit claims were centralized in a federal proceeding in the U.S. District Court, Southern Ditsrict of Illinois. Recent documents indicate that the proceeding was established on October 7th. These claims were filed in the absence of a Lipitor recall.
The Lipitor litigation has grown steadily since February 2012, when the U.S. Food and Drug Administration (FDA) ordered Pfizer Inc. to adjust the drug’s labeling to include the risk for new-onset diabetes. At the time, the federal agency also ordered the company to note Lipitor’s connection to memory loss. This was prompted by the FDA’s receiving patient reports of confusion, forgetfulness and unfocused thinking. Lipitor is a statin medication prescribed to lower cholesterol in patients at risk for developing heart disease, or may be at risk of experiencing heart attacks, stroke, and related heart problems. According to research published in JAMA: Internal Medicine, post-menopausal women were especially likely to develop the disease.
Following these revelations, the British Medical Journal reported in May 2013 the findings of a study that showed patients taking the drug were at a 22 percent increased risk of new-onset diabetes.
The lawyers at Bernstein Liebhard LLP are actively pursuing Lipitor lawsuit claims on behalf of patients who may have been diagnosed with diabetes after taking the cholesterol-lowering statin. If this sounds like you, contact an attorney at the Firm today at .